About this trial
Hemophagocytic lymphohistiocytosis (HLH) associated with hematologic malignancies (HM-HLH) is a syndrome with an abysmal prognosis (10-30% 5 years overall survival). The investigators have recently established an improved diagnostic and prognostic index for HM-HLH, termed the Optimized HLH Inflammatory (OHI) index. The OHI index is comprised of the combined elevation of soluble CD25 (sCD25) \> 3,900 U/mL and ferritin \>1,000 ng/mL . However, the true incidence and outcomes of HLH/OHI+ in an unselected cohort are unknown, and so is the mechanism of HM-HLH.
Eligibility criteria
Qualifiers
Patients with hematologic malignancies
At least 18 years old
Disqualifiers
Prior recent treatment (chemotherapy/ other cytoreductive therapies in the last month)
Trial design
Treatments tested in this trial
- Not listed
Trial groups
Sponsors and collaborators
Meir Medical Center
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Collaborator
Rabin Medical Center
Collaborator
Sheba Medical Center
Collaborator
Schneider Children's Medical Center, Israel
Collaborator